Mount Yale Investment Advisors LLC Sells 16,103 Shares of Bristol-Myers Squibb (NYSE:BMY)

Mount Yale Investment Advisors LLC decreased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,361 shares of the biopharmaceutical company’s stock after selling 16,103 shares during the period. Bristol-Myers Squibb comprises 0.5% of Mount Yale Investment Advisors LLC’s portfolio, making the stock its 22nd largest holding. Mount Yale Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $6,826,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Gryphon Financial Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 23.5% in the 4th quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 995 shares during the period. Clearbridge Investments LLC increased its holdings in Bristol-Myers Squibb by 12.0% during the fourth quarter. Clearbridge Investments LLC now owns 125,980 shares of the biopharmaceutical company’s stock valued at $6,464,000 after buying an additional 13,534 shares during the last quarter. TCW Group Inc. purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth $2,134,000. Avantax Planning Partners Inc. grew its position in shares of Bristol-Myers Squibb by 12.2% during the 4th quarter. Avantax Planning Partners Inc. now owns 9,198 shares of the biopharmaceutical company’s stock valued at $472,000 after acquiring an additional 1,000 shares during the period. Finally, HCR Wealth Advisors increased its stake in shares of Bristol-Myers Squibb by 10.6% in the 4th quarter. HCR Wealth Advisors now owns 14,618 shares of the biopharmaceutical company’s stock worth $750,000 after purchasing an additional 1,405 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $49.41 on Friday. The company has a market capitalization of $100.16 billion, a P/E ratio of -15.94, a P/E/G ratio of 12.59 and a beta of 0.46. The business’s 50-day moving average is $47.68 and its 200 day moving average is $46.45. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $59.46.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same period in the prior year, the company earned $1.75 EPS. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.86%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Upgrades and Downgrades

BMY has been the topic of several analyst reports. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Jefferies Financial Group lifted their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. TD Cowen increased their target price on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a report on Monday, August 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a report on Monday, September 16th. Finally, Barclays increased their price objective on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a research note on Thursday, August 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $55.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.